2023-503679-12-00
Recruiting
Phase 1
A First-in-Human Dose Escalation Study of JNJ-79635322, in Participants with Relapsed or Refractory Multiple Myeloma or Previously Treated AL Amyloidosis
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Janssen - Cilag International
- Enrollment
- 75
- Locations
- 15
- Status
- Recruiting
- Last Updated
- 11 months ago
Overview
Brief Summary
No summary available.
Investigators
CTIS Point of Contact
Scientific
Janssen - Cilag International
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified
Study Sites (15)
Loading locations...
Similar Trials
Completed
Phase 1
Dose Escalation Study of JNJ-63709178, a Humanized CD123 x CD3 DuoBody in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)Leukemia, Myeloid, AcuteNCT02715011Janssen Research & Development, LLC62
Completed
Not Applicable
A Phase 1 first- in-human dose escalation and expansion study for the evaluation of safety, pharmacokinetics, pharmacodynamics and anti-tumor activity of SAR441000 administered intratumorally as monotherapy and in combination with cemiplimab in patients with advanced solid tumorsAdvanced solid tumors10027655NL-OMON55221Genzyme Europe BV11
Recruiting
Phase 1
KSV01 Injection for the Treatment of Relapsed/Refractory Diffuse Large B-Cell LymphomaDiffuse Large B Cell Lymphoma (DLBCL)NCT07260812TCRx Therapeutics Co.Ltd18
Not yet recruiting
Phase 1
First-in-Human Study of RO78126532025-522101-37-00F. Hoffmann-La Roche AG12
Active, not recruiting
Phase 1
A Phase 1, First-in-Human, Dose Escalation Study of the JNJ-75348780 Bispecific Antibody Targeting CD3 and CD22 in Participants with NHL and CRelapsed/refractory B-cell Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)Therapeutic area: Diseases [C] - Neoplasms [C04]CTIS2023-504403-92-00Janssen - Cilag International200